Safety Data Sheet

EVRYSDI® (Risdiplam) 0.75 mg/ml

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name	EVRYSDI® (Risdiplam) 0.75 mg/ml	
Product code	CSE-3277	
Synonyms	- SMN2 (3) RO7034067	*1
	- aqueous solution containing 0.75 mg/ml Risdiplam and excipients	
	- SIP - SMN2 RG7916	*1
	- Risdiplam 0.75 mg/ml	

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use	- pharmaceutical active substance	*1
	- in clinical trials	*1

1.3. Details of the supplier of the safety data sheet

Company information	Enquiries: Genentech, Inc. 1 DNA Way South San Francisco USA-CA 94080 United States of America Phone 001-(650) 225-1000 E-Mail info.sds@roche.com US Chemtrec phone: (800)-424-9300	Local representation:

1.4. Emergency telephone number

Emergency telephone number	US Chemtrec phone: (800)-424-9300
1 referring to:	Risdiplam

SECTION 2: Hazards identification

Classification of the substance or mixture / Label elements

GHS Classification	no classification and labelling according to GHS

Other hazards

Note	- no information available

SECTION 3: Composition/information on ingredients

Characterization	Risdiplam and other inactive ingredients	
Ingredients	**Concentration**	**GHS-Classification (pure ingredient)**
Risdiplam 1825352-65-5	0.075 %	- Acute toxicity (Category 3), H301 - Germ cell mutagenicity (Category 2), H341 - Reproductive toxicity (Category 1B), H360FD - Specific target organ toxicity - Repeated exposure (Category 2), H373
Strawberry Flavour	0.19 %	- Skin corrosion/irritation (Category 2), H315 - Serious eye damage/eye irritation (Category 2A), H319 - Skin sensitization (Category 1A), H317

For the full text of the 'Hazard statements' mentioned in this Section, see Section 16.

***1** referring to: Risdiplam

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye contact	- rinse immediately with tap water for at least 20 minutes - open eyelids forcibly - consult a physician if irritation persists
Skin contact	- remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents
Inhalation	- remove the casualty to fresh air - in the event of symptoms get medical treatment

4.2. Most important symptoms and effects, both acute and delayed

Note	- no information available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physician	- treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media	- water spray jet, dry powder, foam, carbon dioxide - adapt extinguishing media to surrounding fire conditions

Flash point (liquid)	not applicable

5.2. Special hazards arising from the substance or mixture

Specific hazards	- formation of toxic and corrosive combustion gases (nitrogen oxides (NOx)) possible

5.3. Advice for firefighters

Protection of fire-fighters	- precipitate gases/vapours/mists with water spray
Special method of fire-fighting	- if possible precipitate fire gases with a water jet

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions	- avoid exposure

6.2. Environmental precautions

Environmental protection	- no special environmental precautions required

6.3. Methods and material for containment and cleaning up

Methods for cleaning up	- collect spilled solutions with inert adsorbent and hand over to waste removal - flush afterwards with plenty of water

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Technical measures	- avoid formation of aerosols - no special measures necessary if stored and handled as prescribed
Suitable materials	- dark glass, stainless steel

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions	- protected from heat and light
Packaging materials	- amber glass ampoules - glass vials, brown

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (Roche) air	-	IOEL (Internal Occupational Exposure Limit): 2 µg/m3	*1
PNEC	-	0.73 µg/l, surface freshwaters, based on acute data	*1

8.2. Exposure controls

Respiratory protection	-	Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls.
	-	breathing apparatus in case of aerosol mist formation
Hand protection	-	protective gloves (eg made of neoprene, nitrile or butyl rubber)
Eye protection	-	safety glasses

1 referring to: Risdiplam

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Color	greenish-yellow to yellow	
Form	clear solution	
Solubility	0.406 mg/l, water (20 °C, pH 7.7, OECD No. 105)	*1
Partition coefficient	log P_{ow} 0.58 (octanol/water°C) pH 7 (HPLC Method, OECD No. 117)	*1

9.2. Other information

Note	-	no information available

1 referring to: Risdiplam

SECTION 10: Stability and reactivity

10.1. Reactivity

Note	-	no information available

10.2. Chemical stability

Stability	-	stable under the conditions mentioned in chapter 7

10.3. Possibility of hazardous reactions

Note	- no information available

10.4. Conditions to avoid

Conditions to avoid	- warming - light

10.5. Incompatible materials

Note	- no information available

10.6. Hazardous decomposition products

Note	- no information available

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity	-	MTD	> 10	mg/kg	(oral, mouse)	*1
	-	NOEL	10	mg/kg	(oral, rat)	*1
Subacute toxicity	-	NOEL	2.5	mg/kg/d	(oral, rat, 14 d)	
		NOAEL	7.5	mg/kg/d	(oral, rat, 14 d)	*1
	-	MTD	20	mg/kg/d	(oral, mouse, 7 d)	*1
Local effects	-	skin: non-irritant				*1
	-	may penetrate the skin (based on animal data)				*1
	-	eye: functional effects (in vitro)				*1
	-	not phototoxic (In Vitro; 3T3 fibroblast Neutral Red uptake assay (in vitro))				*1
Sensitization	-	not skin sensitizing (mouse) (OECD No. 429, LLNA (Local Lymph Node Assay))				*1
Mutagenicity	-	negative (Ames test; OECD No. 471 (Salmonella typhimurium))				*1
	-	positive (OECD No. 487 (In vitro Mammalian Cell Micronucleus Test))				*1
	-	genotoxic (clastogen); no direct DNA reactivity				*1
	-	positive (test system in vivo; OECD No. 474 (Micronucleus Test))				*1
Carcinogenicity	-	not classified as carcinogenic				*1
Reproductive toxicity	-	based on its mechanism of action, effects on embryofetal development can be assumed				*1
	-	NOAEL (maternal toxicity and embryo-fetal development) (4 mg/kg/d, rabbit, female, 14 d)				*1
	-	embryo-fetal lethality evidenced by increased number of late resorptions and fetal malformation (12 mg/kg/d, rabbit, female, 14 d)				*1
	-	NOAEL = 3 mg/kg/d (rat, female, 12 d)				*1

	- retarded fetal development (7.5 mg/kg/d, rat, female, 12 d)	*1
STOT-single exposure	- no information available	
STOT-repeated exposure	- may cause damage to organs (gastrointestinal system, skin, eye, testes) through prolonged or repeated exposure	***1**
Aspiration hazard	- no information available	
Potential Health Effects	- Exposure: Inhalation, Ingestion, Skin contact, Eye contact	
	- Carcinogenicity: not listed by NTP, IARC or OSHA	

1 referring to: Risdiplam

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity	- highly toxic for planktonic crustaceans (Daphnia magna) EC_{50} (48 h) 0.732 mg/l NOEC (48 h) 0.28 mg/l (OECD No. 202, semistatic)	*1
	- no adverse influence on substrate biodegradation (activated sludge) concentration (14 d) 35.0 mg/l (Manometric Respirometry Test, OECD No. 301 F)	*1

12.2. Persistence and degradability

Ready biodegradability	- not readily biodegradable 0 %, 28 d (Manometric Respirometry Test, OECD No. 301 F)	*1
Abiotic degradation	- not abiotically degradable (Manometric respirometry test, OECD no. 301 F, abiotic control)	*1

12.3. Bioaccumulative potential

Note - no information available

12.4. Mobility in soil

Note - no information available

12.5. Results of PBT and vPvB assessment

Note - no information available

12.6. Other adverse effects

Note	-	no information available
1 referring to:		Risdiplam

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues	-	observe local/national regulations regarding waste disposal - incinerate in qualified installation with flue gas scrubbing

SECTION 14: Transport information

Note	-	not classified as Dangerous Good according to the Dangerous Goods Regulations, proper shipping name non-regulated

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

TSCA Status	-	FDA Exemption - not on inventory
Reporting Requirements	-	The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material. - In New Jersey, report all releases, which are likely to endanger the public health, harm the environment or cause a complaint, to the NJDEPE Hotline and to local officials. - State and local regulations vary and may impose additional reporting requirements.

SECTION 16: Other information

Full text of H-Statements referred to under section 3

H301	Toxic if swallowed.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H341	Suspected of causing genetic defects.
H360FD	May damage fertility. May damage the unborn child.
H373	May cause damage to organs through prolonged or repeated exposure.

Edition documentation	-	changes from previous version in sections 9

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.